Morphotek Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Exton PA United States (2000)
Status: Acquired by Eisai (2007) → now Sarepta Therapeutics (2014)

Organization Overview

First Clinical Trial
2005
NCT00428766
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Morphotek Clinical Development Section, JAC PCU